Neuronetics, Inc.

Neuronetics, Inc. announced the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. This nearly 7,000-square-foot facility is the largest Greenbrook center to date and will serve as a national blueprint for advanced, patient-centered mental health care. It aims to expand access to advanced treatment options, accelerate clinical innovation, and improve patient outcomes, offering NeuroStar TMS and SPRAVATO therapies, and acting as a pilot site for emerging modalities.

Neuronetics, Inc. announced significant management changes, including the appointment of Nir Naor as Executive Vice President, Chief Financial Officer, and Treasurer, effective July 23, 2026. Mr. Naor brings over 20 years of finance and life sciences experience, previously serving as CFO at Axogen, Inc. Concurrently, W. Andrew Macan, Executive Vice President, Chief Legal Officer, and Corporate Secretary, will depart on August 15, 2026, receiving a retention bonus, vested RSUs, and a separation payment. Additionally, Cory Anderson was promoted to Executive Vice President and General Manager of Greenbrook, effective July 1, 2026.

Neuronetics, Inc. announced that its management will participate in the B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event. The company's management will join a panel discussion titled "Commercializing the Next Wave of Novel Neuropsychiatric Drugs" alongside Compass Pathways on July 16, 2026. Additionally, management will be available for one-on-one meetings with institutional investors throughout the day.

Neuronetics, Inc. announced the promotion of Cory Anderson to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026. Mr. Anderson previously held the position of Senior Vice President, Chief Technology Officer. In connection with his promotion, his annual base salary will increase to $425,000, and his target annual cash bonus will be 45% of his base salary. He will also continue to be eligible for annual equity grants.

Neuronetics, Inc. announced the appointment of Robert Greene as Senior Vice President Sales, effective June 1, 2026. Mr. Greene brings extensive experience in leading commercial strategy and sales organizations within the healthcare and medical technology sectors. In connection with his hiring, the company's Compensation Committee authorized an inducement grant of 200,000 restricted stock units to Mr. Greene, which will vest in four equal annual installments.

Neuronetics, Inc. announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society (CTMSS) Annual Meeting. The company will present real-world data from its proprietary TrakStar database in an oral presentation and multiple scientific posters, focusing on advancing the understanding of transcranial magnetic stimulation (TMS) for mental health conditions. This involvement underscores Neuronetics' commitment to innovation, scientific leadership, and expanding evidence-based treatment options. Additionally, Neuronetics will demonstrate NeuroStar's navigation capabilities at the PULSES Course.

Neuronetics, Inc. announced an amendment to the consulting agreement with Francis X. Brown III, the Interim Principal Financial and Accounting Officer (PAO). The amendment clarifies that Mr. Brown will continue in his role until the company employs a full-time controller and a full-time principal financial and accounting officer, or another mutually agreed date. Additionally, his compensation was updated from a fixed $25,000 for his services to a monthly rate of $26,000.

Neuronetics, Inc. announced a strategic partnership with ANT Neuro to integrate ANT Neuro’s visor2™ neuronavigation system with its NeuroStar® Advanced Therapy System. This collaboration aims to enhance treatment visualization, consistency, and personalization for Transcranial Magnetic Stimulation (TMS) workflows by combining NeuroStar's contact sensing technology with visor2™'s real-time spatial tracking and 3D visualization. The partnership will be showcased at upcoming industry meetings, with a broader rollout anticipated in the second half of 2026.

Neuronetics, Inc. reported a substantial doubt about its ability to continue as a going concern, primarily due to a projected failure to meet its March 31, 2027 minimum revenue covenant, which could lead to its lender calling the credit facility. Despite this, the company's Q1 2026 financial results showed an increase in total revenue by 7.7% to $34.45 million and a narrowed net loss to $(10.78) million. Cash and cash equivalents, however, significantly decreased to $13.21 million from $28.13 million at the end of 2025.

Neuronetics reported Q1 2026 revenue of $34.5 million, an 8% increase year-over-year, with U.S. clinic revenue growing 15% to $21.5 million. The net loss narrowed to $(10.8) million, or $(0.16) per share, from $(12.7) million in Q1 2025. Net cash used in operations significantly decreased by $7.6 million to $9.4 million. Additionally, Optum/UHC/UBH expanded its TMS clinical policy to allow nurse practitioners to administer NeuroStar Advanced Therapy, broadening access for approximately 34.8 million covered lives. The company maintained its full-year 2026 revenue guidance.